BMS rivals pushed bidding on Inhibitex; Janssen opens lab for biotech startups; Array CEO resigns;

@FierceBiotech: Constellation inks $95M discovery deal, buyout option with Genentech on new epigenetic drug programs. News | Follow @FierceBiotech

@JohnCFierce: Say goodnight, gracie. Dimebon fails final Ph3, Pfizer dumps monster partnership. Release | Follow @JohnCFierce

@MarkHFierce: Researchers are challenging studies that linked hormone replacement therapy to cancer based on "flawed" data. More | Follow @MarkHFierce

@RyanMFierce: Verastem's IPO plan seems to me like a bet on people as much as promise of new cancer stem cell targets. Article | Follow @RyanMFierce

> Anyone trying to figure out the dynamics behind the recent eye-popping buyouts of hepatitis C drug developers should check out a report from Bloomberg late last week, which tracked down the interesting fact that Bristol-Myers Squibb raised its bid for Inhibitex twice in five days as it countered offers from an unnamed rival. BMS began its courtship of the biotech with a $550 million bid last October, ending at nearly 5 times that amount by the time the dust had settled. Story

> J&J's Janssen Research & Development has opened up a 30,000 square foot lab in San Diego designed to cater to startup biotechs in the area. Release

> Six months after cutting back its workforce, Array BioPharma announced that CEO Robert Conway has resigned, citing personal reasons for the departure. Release

> Valeant ($VRX) bumps its offer to buy ISTA Pharmaceuticals by at least 15%. Story

> Alnylam ($ALNY) has filed a suit against Tekmira claiming patent infringement of its RNA technology. Release

Pharma News

 @FiercePharma: Launch angst among investors, analysts say: 'People are all freaked out'--Reuters. Article | Follow @FiercePharma

> Bit by bit, Lundbeck trims fat from production costs. Article

> Generics market to bulk up by $100B in 5 years. Story

Biotech Research News

> Sugar molecules betray precancerous cells in esophagus. More

> Hormone irisin eyed as possible weight loss drug ingredient. Item

> Vitamin D helps (more than) 3 (nearly) blind mice see. Article

> PARP inhibitors could aid larger ovarian cancer patient population. News

> Altering intestional bacteria with probiotics improved rats' heart health. Story

IT News

> Cannabis company launches Jane-Ome app. Item

> PerkinElmer CEO arranges marriage between informatics, lab service biz. More

> Entelos stages comeback bid with funding. Article

> AB Sciex, Indigo BioSystems join forces on mass spectrometry software. Story

> DecisionView updates clinical trial enrollment software. News

Manufacturing News

> Roche pilots direct shipments to Europe. News

> Abbott dodges excise tax at Indian plant. Story

> Daiichi sends Japanese execs to new Ranbaxy plant in India. More

> FDA: Novartis plant shows patterns of problems. Story

> USP has credibility as pedigree driver. Article

And Finally... A new "smart" pill has been developed that helps keep patients on track with their drug regimen. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.